A Convergence of Crises in Healthcare

Specialty pharmacy costs are breaking healthcare economics. With biologics like Humira at $8,100/month, Dupixent at $65,000/year, and newer therapies exceeding $370,000 annually, the financial pressure is compounded by rapidly increasing utilization – 75% of the FDA pipeline is biologics. Employers face projected benefit cost increases of 6.5% in 2026, with 92% expressing serious concern about specialty pharmacy costs.

But there’s a deeper problem: these expensive medications frequently don’t work. TNF inhibitors see 10-30% primary non-response, with another 23-46% losing response during maintenance. In psoriasis, biologic survival drops from 66-82% at year one to just 41-56% by year four. Up to 40% of RA patients respond inadequately to initial anti-TNF treatment.

The result? Employers pay tens of thousands annually for medications that fail 20-40% of patients initially and nearly half of remaining patients within years.

Meanwhile, our prior authorization process only checks boxes—it doesn’t evaluate effectiveness. Overwhelmed by GLP-1 volume, many organizations deploy AI to accelerate approvals, inadvertently driving up spending. No one is asking the critical question: Is the medication actually working?

A Clinical Efficacy Solution

We founded Ethicos Health two years ago after seeing these crises collide — skyrocketing costs, widespread inefficacy, and outdated systems. Our goal was to build a solution that tackles the specialty pharmacy problem by both lowering costs and making sure patients are on medications that actually work. Ethicos Health gives plan sponsors the clarity they need to cover therapies based on real clinical effectiveness.

Specialty medications are highly targeted and this specificity means they’re ineffective for many patients taking them – while employers spend millions on therapies that fail to deliver. By helping plan sponsors pay only for treatments that actually work, they can afford to cover these critical medications for patients who benefit, while lowering specialty pharmacy costs and keeping healthcare affordable. The insight that drove us was simple but powerful: by aligning coverage with outcomes – not by denying access – we can make healthcare affordable again.

These are not theoretical concerns. Every day, patients start costly therapies that won’t work for them – at best, they’re just expensive; at worst, they carry dangerous side effects.  Every day, employers struggle to maintain coverage for medications they can barely afford. And every day the system fails to deliver value for both patients and payers.

A Clinical Efficacy approach honors both fiscal responsibility and patient welfare.

The principle is straightforward: plans should pay for medications only when they demonstrably work for individual patients, as measured by whether they achieve their intended clinical endpoints. This isn’t about denying care or creating barriers. It’s about ensuring that the substantial resources we devote to specialty pharmacy actually translate into meaningful clinical outcomes.

By serving as an “honest broker,” our platform allows plans to measure clinical efficacy to inform coverage decisions – rather than making eligibility determinations based solely on rebates, formularies, or financial arrangements that may not align with patient interests. Our platform allows plans to certify and re-certify medications based on whether they’re achieving their clinical goals for each member—nothing more, nothing less.

Creating Value for Everyone

This approach generates meaningful benefits across the healthcare ecosystem:

For employers and plan sponsors, it offers a sustainable path forward. By covering specialty medications only when they work, plans can actually afford to provide access to these important therapies for those who truly benefit. This is especially critical as 75% of drugs in the FDA pipeline are biologics—the train is coming down the tracks, and we need sustainable solutions before it arrives.

For health plans, our model reduces administrative cost by allowing clinicians to focus on complex “corner cases”, while enabling transparent, clinically-grounded decisions that can be clearly communicated to patients and providers. There’s no ambiguity about why a medication is or isn’t covered – the answer is always rooted in clinical reality, providing a better member and provider experience.

For patients, perhaps most importantly, those on effective therapies can be fast-tracked or “gold-carded” without the frustration of prior authorization processes. If a medication is working, plans can eliminate bureaucratic friction entirely. And for those on ineffective treatments, it creates the opportunity to pivot quickly to alternatives that might actually help.

For providers, it presents a transparent request that clearly articulates which data points are being evaluated to make coverage decisions – eliminating the guesswork about which data matter and reducing time and frustration. Ultimately, it lowers the administrative burden of justifying treatments that are clearly working while maintaining appropriate oversight for those that aren’t.

Enabling the Path to Value-Based Drug Contracting

What excites me most about this model is its potential to enable true value-based drug contracting by generating the data plans need to pay only when a drug is actually working. Instead of coverage decisions driven by rebates or formulary positioning, we can finally align payment with real clinical performance. It lets us answer the fundamental question that should guide all healthcare: Is this treatment helping this patient?

Moving Forward with Hope

Our team brings deep experience as healthcare operators who have witnessed firsthand how specialty pharmacy costs threaten the sustainability of employer-sponsored coverage. We’ve seen the impossible choices that benefit managers face, the frustration of providers unable to access therapies they know could help, and the devastation of patients who begin expensive treatments only to find them ineffective.

We’re currently working with transparent PBMs and health plans who share our vision – organizations seeking solutions for employers overwhelmed by GLP-1 costs and other specialty medications. These are employers who want desperately to cover life-changing therapies but cannot sustain current trajectories.

The challenge ahead is significant, but so is the opportunity. We have a chance to fundamentally reshape how healthcare resources are allocated—to pivot from a system where cost alone determines access to one where clinical efficacy guides coverage decisions.

This isn’t about restricting care. It’s about making sure that every dollar spent on specialty pharmacy translates into genuine clinical benefit. It’s about building a system where innovation can flourish because we’ve created sustainable economics around proven outcomes.

We believe this is possible. We believe it’s necessary. And we’re committed to making it real.

If you’re interested in learning how our Clinical Efficacy Platform can help lower the cost of specialty pharmacy while improving clinical outcomes, I’d welcome the conversation.

Interested in learning more about how Ethicos Health’s platform works? Email contact@ethicoshealth.com to discuss how we’re helping plans manage specialty pharmacy costs while ensuring patients get the medications that actually work for them.